Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY27 revenue growth guidance is around 25%, with EBITDA margins targeted between 20%-22%. Tatva Chintan expects revenue growth of around 25% for FY27, driven by segments like Electrolyte Salts (ESS), Pharma, Agro, Specialty Chemicals (PASC), and Structured Directing Agents (SDA).
From Tatva Chintan Pharma Chem Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY27 revenue growth guidance is around 25%, with EBITDA margins targeted between 20%-22%.
- Structured Directing Agents (SDA) expected to grow at least 20% in FY27, reaching INR250-300 crores.
- Electrolyte Salts segment to become a relevant contributor, targeting 8%-10% of overall revenue, with ramp-ups continuing through FY27 and beyond.
- Pharma segment to add INR70-75 crores in FY27 through new product commercialization.
- Agro intermediates demand is stable with improved commercial traction; new product launches expected post-Jolva plant commissioning (~early 2028).
- Semiconductor chemicals segment beginning commercial dispatch with gradual scale-up expected through 2027-28.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current financial year (FY27) capex: INR 100 crores, mainly for Jolva plant.
- Next financial year (FY28) capex: INR 175 crores, also largely for Jolva plant.
- Total estimated investment for Jolva project: approx. INR 250-270 crores.
- Jolva plant construction expected to start by mid-2026, with commercial production targeted in early 2028 (January to March).
- Additional minor capex (~INR 10-12 crores per year) planned to remove bottlenecks and ramp up revenue at existing Dahej facility.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company receives annual forecasts from customers and orders are released based on these forecasts.
- Forecasts are generally precise except during unpredictable demand fluctuations.
- Demand became volatile over the last 2 years due to inventory pile-ups post-COVID but is now normalizing with regular orders.
- For the Pharma, Agro, and Specialty Chemicals (PASC) segment, there is good visibility of orders till the end of the current calendar year and likely continuation into the next year.
- Semiconductor chemicals segment is at the early commercialization stage with first plant scale batch dispatch expected this quarter; gradual scale-up expected through 2028-29.
2 more points management made on order book & pipeline
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹134 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
- Chemfab Alkalis Ltd (Q4 FY26)
Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…
- Sudarshan Pharma Industries Ltd (Q4 FY26)
Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…
- Innovassynth Technologies (India) Ltd (Q4 FY26)
Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q4 FY26 results?
FY27 revenue growth guidance is around 25%, with EBITDA margins targeted between 20%-22%. Tatva Chintan expects revenue growth of around 25% for FY27, driven by segments like Electrolyte Salts (ESS), Pharma, Agro, Specialty Chemicals (PASC), and Structured Directing Agents (SDA).
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
Current financial year (FY27) capex: INR 100 crores, mainly for Jolva plant. - Next financial year (FY28) capex: INR 175 crores, also largely for Jolva plant. - Total estimated investment for Jolva project: approx.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.